<DOC>
	<DOC>NCT02724358</DOC>
	<brief_summary>In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.</brief_summary>
	<brief_title>Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>1. Pathologically confirmed hepatocellular carcinoma. 2. High expression of Notch1 in tumor tissues. no pathological evidence of HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Hepatocellular</keyword>
	<keyword>Notch1</keyword>
</DOC>